Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in <scp>Bardet‐Biedl</scp> syndrome

Abstract

Setmelanotide reduced body weight and hunger in individuals with BBS and had a safety profile consistent with previous reports. Setmelanotide may be a treatment option in individuals with BBS-associated obesity and hyperphagia.